Sodium-Glucose Cotransporter 2 Inhibitors: An Overview

Document Type

Article

Publication Date

10-13-2017

Abstract

The management of type 2 diabetes (T2DM) has evolved significantly over the past several decades. One of the newest additions to antidiabetic therapy is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with a unique mechanism that targets the kidney’s ability to reabsorb filtered glucose. In addition to providing glycemic control, this class has a unique mechanism of action associated with blood pressure reduction, weight loss, and potential cardiovascular benefits; however, the FDA is closely monitoring the use of these drugs based on increased safety concerns. The benefits and risks of SGLT2 inhibitors should be carefully considered. Selected patients with T2DM can benefit from SGLT2 inhibitor therapy.

Publication Title

U.S. Pharmacist

Volume

42

Issue

10

First Page

42

Last Page

46

Comments

This article was published in U.S. Pharmacist, Volume 42, Issue 10, Pages 42-46.

The published version is available at https://www.uspharmacist.com/article/sodiumglucose-cotransporter-2-inhibitors-an-overview.

Copyright © 2017.

This document is currently not available here.

COinS